drugset / Trial / NCT00635531

A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder

NCT00635531 ↗

Phase 4 Terminated 16 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics of alprazolam extended release (XR) for the treatment of adolescents with panic disorder

Timeline

Start
2004-04
Primary completion
—
Completion
2004-09

Outcome

Outcome not reported

Stopped: “Please see Detailed Description for termination reason.”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alprazolam Small molecule 6 mg Oral

Indications